Key Financial Figures - Standalone (Quarter Ended June 30, 2026)
Revenue from Operations: ₹8.00 lakhs (Interest Income)
Other Income: ₹1.29 lakhs
Total Income: ₹9.29 lakhs
Total Expenses: ₹60.72 lakhs
Finance Costs: ₹8.26 lakhs
Employee Benefit Expense: ₹0.00 lakhs
Depreciation: ₹2.16 lakhs
Other Expenses: ₹50.30 lakhs
Loss Before Tax: ₹(51.43) lakhs
Net Loss After Tax: ₹(51.43) lakhs
Other Comprehensive Income: ₹0.18 lakhs
Total Comprehensive Loss: ₹(51.25) lakhs
Basic/Diluted EPS: ₹(0.16) per share (face value ₹10)
Paid-up Equity Capital: ₹3,181.05 lakhs
Key Financial Figures - Consolidated (Quarter Ended June 30, 2026)
Revenue from Operations: ₹44,684.98 lakhs
Interest Income: ₹2.22 lakhs
Dividend Income: ₹632.51 lakhs
Net gain on fair value changes: ₹(460.82) lakhs
Sale of products: ₹43,956.89 lakhs
Sale of services: ₹72.34 lakhs
Other financial income: ₹1.18 lakhs
Other Income: ₹1,282.98 lakhs
Total Income: ₹45,967.96 lakhs
Total Expenses: ₹45,770.48 lakhs
Finance Costs: ₹59.39 lakhs
Cost of materials consumed: ₹17.20 lakhs
Purchases of stock-in-trade: ₹44,797.59 lakhs
Employee benefit expense: ₹2,768.47 lakhs
Depreciation: ₹188.82 lakhs
Other Expenses: ₹2,144.83 lakhs
Profit Before Tax: ₹197.48 lakhs
Tax Expense: ₹(1.19) lakhs
Net Profit After Tax: ₹198.67 lakhs
Total Comprehensive Income: ₹138.67 lakhs
Basic/Diluted EPS: ₹0.80 per share
Director Reappointment Details
Name: Mrs. Anjana Dikshit (DIN: 10377490)
Role: Reappointment as Independent Director
Term: Second term of 5 consecutive years
Effective Date: November 10, 2026
Condition: Subject to shareholder approval before conclusion of first term
Profile: IT professional, former Associate Director at IBM India (ERP Practice), mechanical engineer from BIT Mesra, PGDM from XLRI Jamshedpur
Relationships: Not related to any directors or promoters of the Company
Corporate Developments
Composite Scheme: Board approved composite scheme of arrangement and amalgamation among Health X Platform Limited, Microsec Resources Private Limited, Innogrow Technologies Limited, and Sastasundar Healthbuddy Limited
Appointed Date: April 1, 2026 (subject to approvals)
Expenses: Incurred ₹14.75 lakhs during quarter for proposed scheme, included in Other Expenses
Segment Reporting: Company operates in Financial Services, Healthcare Network, and Other segments
Auditor Qualifications
Standalone: Limited review report by JKVS & Co. Chartered Accountants - no material misstatements found
Consolidated: Emphasis of matter regarding Genu Path Labs Limited (step-down subsidiary) - net worth completely eroded, current liabilities exceed current assets, but financial statements prepared on going concern basis due to continued financial support from Sastasundar Healthbuddy Limited
Subsidiary Coverage: Includes 14 subsidiaries with varying levels of auditor review
Meeting Details
Board Meeting Date: August 7, 2026
Commencement: 3:30 PM
Conclusion: 4:25 PM
Approvals: Audit Committee reviewed results before board approval
